Oral pharmaceutical composition of glp-1 receptor agonist and preparation method therefor
WO2025252098A1PCT designated stage Publication Date: 2025-12-11HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
Patent Information
- Application Number
- PCT/CN2025/098931
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-06-05
- Filing Date
- 2025-06-04
- Publication Date
- 2025-12-11
Smart Images

Figure PCTCN2025098931-FTAPPB-I100001 
Figure PCTCN2025098931-FTAPPB-I100002 
Figure PCTCN2025098931-FTAPPB-I100003
Abstract
A pharmaceutical composition containing (S)-2-((4-(6-((2-fluoro-4-(oxetan-3-yl)benzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid ("OAD2") or a pharmaceutically acceptable salt thereof, and a preparation method for the pharmaceutical composition. The dissolution of the provided pharmaceutical composition is good, the total content of impurities is low, and the pharmaceutical composition can be stably stored under normal temperature and humidity conditions.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
GLP-1 receptor agonists and uses thereof
CN110325530A
GLP-1 small molecule with cardiovascular benefits
CN113773310A
Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl) oxy] pyridin-2-yl} piperidin-1-yl) methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazol-6-carboxylic acid or pharmaceutical salt thereof
CN115348863A
Heterocyclic GLP-1 agonists
CN116547279A
GLP-1 receptor agonist and composition and application thereof
CN117362283A